Vitamins in cholestasis

Newborn use only

Alert	The dose recommendations for cholestasis are based on expert opinion. International units (IU) are labelled as units in this formulary.									
	Bio-Logical Vitamin A oral solution and OsteVit D oral liquid contains sodium benzoate. Avoid exposure of									
	>99mg/kg/day in neonates.									
Indication	Neonatal cholestasis									
Action			amin regui	red for vision	ı, growt	th and b	one devel	opme	ent, immune fu	nction and
	Vitamin A: Fat soluble vitamin required for vision, growth and bone development, immune function and maintenance of epithelial cells particularly in the retina and respiratory tract tissues.									
		-	•	-			-			
	Vitamin D: Regulating levels of calcium and phosphorus and mineralisation of bone. Vitamin E: Antioxidant protecting cell membranes from oxidative stress. Active isomer is α -tocopherol. Vitamin K: Promotes the activation of blood coagulation Factors II, VII, IX and X in the liver.						copherol.			
Drug type	Fat and water soluble vitamins									
Trade name	Pentavite Infant liquid 0-3 years									
	Bio-Logical Vitam	in A ora	l solution							
	Ostelin Vitamin-D	3 1000	IU liquid							
	Pretorius Micel-E	oral liq	uid							
	Konakion MM Pa									
Presentation	Pentavite Infant – Each 0.45 mL contains 1287 units of vitamin A and 400 units of vitamin D.									
	Bio-Logical Vitam									
	Ostelin Vitamin -I	•	•	•				f vitar	nin D.	
	Pretorius Micel-E						min E.			
	Konakion MM Pa			ontains 2 mg	vitamir	1 K ₁ .				
Dose	Suggested starting			1			./_			
			amin A	Vitamin			min E		Vitamin	
	Dose range	3000-	5000 units	1000-2000		15-3	0 units	2 m	ng twice a wee	k up to 2 mg
	per day (not			(25-50 _L	rg)				daily	
	per kg)	per kg)								
	Medical office	Medical officers to prescribe the following Dose Range								
		-			Vitamin A Vitamin D					
	Vitamins		Oral pre	paration		nits)	(units		(units)	(mg)
		4								
			Dose (mL) and							
			Frequency							
	Pentavite Infant 0.45 mL once or twice daily 1287-2574 400-800 - (10-20 μg)				1287-2574			-	-	
						(10-20 μg)		<u> </u>		
			0.1 mL daily*		2500		-		-	-
			0.5 mL daily*							
						-			-	-
	units/0.5 mL#	_	0.4.0.0						45.6.04.0	
	Pretorius Micel- liquid	·E	0.1-0.2 mL daily*			-	-		15.6-31.2	-
	Konakion MM		0.2 mL twice a week to					-	2 mg twice	
			da	ily						a week to 2
	Paediatric									mg daily
	Paediatric									
	Paediatric			Total	3787	-5074	1400-18	300	15.6-31.2	2 mg twice
	Paediatric			Total	3787	-5074	1400-18 (35-45)		15.6-31.2	2 mg twice a week to 2
	Paediatric			Total	3787	-5074			15.6-31.2	_
	*The daily dose n	-	administere	ed in two divid	ded dos	ses.	(35-45	ug)		a week to 2 mg daily
	*The daily dose n	D is the	administere preferred I	ed in two divid	ded dos e it doe	ses.	(35-45	ug)		a week to 2 mg daily
	*The daily dose n *Ostelin Vitamin- strengths in each	D is the	administere preferred I	ed in two divid	ded dos e it doe	ses.	(35-45	ug)		a week to 2 mg daily
Dose adjustment Maximum dose	*The daily dose n	D is the	administere preferred I	ed in two divid	ded dos e it doe	ses.	(35-45	ug)		a week to 2 mg daily

Vitamins in cholestasis

Newborn use only

Total cumulative dose						
Route	Oral					
	No preparation is required					
Preparation Administration	Administer undilute					
Monitoring			E and PT/INR in 1-3 month	aly May need more fro	auent monitoring in	
Worldoning	the initial weeks of		Land 1 1/1111 III 1-3 IIIond	ily. Way fieed filore fre	Equent monitoring in	
Contraindications			or any component of the	formulations.		
	Hypersensitivity to vitamin A, D, E, K or any component of the formulations. Hypervitaminosis of A, E and/or D.					
Precautions	711-11-11-11-11-11-11-11-11-11-11-11-11-	,, -				
Drug interactions	May increase effects of anticoagulant and antiplatelet agents					
Adverse reactions	Hypervitaminosis A: Irritability, lethargy, vomiting, bulging fontanelle.					
	Hypervitaminosis D	: Hypercalcaemia	, nephrocalcinosis.			
	Vitamin E: Potentia	tion of coagulopa	thy, sepsis, necrotising en	terocolitis.		
Compatibility	Not applicable					
Incompatibility	Not applicable					
Stability	-		weeks after opening.			
	Other vitamins: Ref					
Storage	All products: Store		9			
	Pentavite Infant liq					
Excipients			arin, pineapple flavour.			
	Bio-Logical Vitamin					
	OsteVit-D oral liqui		te, caramei flavour. um sorbate and soy bean j	oroducts		
		•	c acid, lecithin, sodium hy		ocid	
Special comments	Vitamin E 1 unit = 0			uroxide, rrydrocinoric a	iciu.	
Special comments	1 mg of retinyl paln					
Evidence	Background	Treate 1919 dine	5 Or Occurrent 7 to			
	_	alence of vitamin	deficiency in neonatal ch	olestasis, with one stu	dy reporting rates of	
			in D (61%), vitamin A (29%			
	serum levels should	be monitored fre	equently in all cholestatic	infants to avoid life thi	reatening	
	bleeding (vitamin K deficiency), bone fractures and rickets (vitamin D deficiency), corneal/retinal defects					
		min A deficiency),	and neurologic and musc	ular abnormalities (vita	amin E deficiency). ⁽⁵⁾	
	Efficacy					
	Dosing recommendations for vitamins in neonatal cholestasisvary and are based on expert opinions. (1-4) Many infants will require individual supplementation of vitamins D, A, E, or K, along with the preferred multivitamin formulation. (5)					
			ıble vitamins are as follow	ıc.		
	Author	Vitamin A	Vitamin D	Vitamin E	Vitamin K	
	Feldman ⁽⁴⁾	3000-10000	800-5000 IU/day OR	Maintain serum	2.5- 5 mg twice a	
	Teluman	U/day	1,25 OH ₂ D3: 0.05-0.2	targets. No dose	week to every day	
		o,,	μg/kg/day	recommendations.	,,	
	Italian society ⁽¹⁾	5000-25000	800-5000 U/day	15-25 U/kg/day	2.5-5 mg twice a	
		IU/day	, ,	,	week to every day	
	King's college,	1333-5000	1000-3000 IU/day	15-150 U/kg/day	1 mg/day	
	London ⁽³⁾	IU/day				
	Lane et al. ⁽²⁾	5000-50000	1000-8000 IU/day	1 unit/kg/day	ORAL:2.5-5 mg	
	Lane et al.	IU/day	1000-8000 10/day	1 unit/kg/uay	IM/SQ/IV: 1-10	
		.5, 44			mg/dose	
	Optimal approach v	vould be to adjust	t the doses based on targe	et serum levels. Refer t		
	Safety				1	
	<u>-</u>	itamins can lead	to adverse effects listed ir	n adverse reactions. ⁽¹⁾		

Vitamins in cholestasis

Newborn use only

Practice points	Aim to maintain the normal range of serum vitamin A, E and D levels. Reference values may vary. Check with your local laboratory.					
	Published recommendations of INR ≤1.2 is often not possible in practice despite high doses of vitamin K.					
	Higher INR values are often accepted as long as there is no clinical evidence of coagulation dysfunction.					
References	1. Dani C, Pratesi S, Raimondi F, Romagnoli C. Italian guidelines for the management and treatment of					
	neonatal cholestasis. Italian Journal of Pediatrics. 2015;41:1-12.					
	2. Lane E, Murray KF. Neonatal cholestasis. Pediatric Clinics. 2017;64:621-39.					
	3. Mancell S, Islam M, Dhawan A, Whelan K. Fat-soluble vitamin assessment, deficiency and					
	supplementation in infants with cholestasis. Journal of Human Nutrition and Dietetics. 2022;35:273-9.					
	4. Feldman AG, Sokol RJ. Neonatal cholestasis. Neoreviews. 2013;14(2):e63-e73.					
	5. Feldman AG, Sokol RJ. Neonatal Cholestasis: Updates on Diagnostics, Therapeutics, and Prevention.					
	NeoReviews. 2021;22:e819-e36.					

VERSION/NUMBER	DATE	
Original 1.0	21/07/2022	
Current 1.0(Minor errata)	10/08/2023	
Current 1.0 (Minor errata)	28/09/2023	
REVIEW	21/07/2027	

Authors Contribution

	
Original author/s	Srinivas Bolisetty
Evidence Review	Srinivas Bolisetty, Kate Dehlsen
Expert review	Kate Dehlsen, Scott Nightingale, Michael Stormon, Usha Krishnan, Lizsa Tan, Katie Marks, Andrea Horvath
Nursing Review	Eszter Jozsa, Sarah Neale
Pharmacy Review	Mohammad Irfan Azeem, Thao Tran
ANMF Group contributors	Nilkant Phad, Bhavesh Mehta, John Sinn, Rebecca Barzegar, Kate Dehlsen, Helen Huynh, Michelle
	Jenkins, Stephanie Halena, Renae Gengaroli
Final editing	Thao Tran
Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty

